Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

INSILICO MEDICINE

InSilico Medicine Cayman TopCo
英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

POSITIVE PROFIT WARNING

This announcement is made by InSilico Medicine Cayman TopCo (the "**Company**", together with its subsidiaries, the "**Group**" or "**Insilico Medicine**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders (the "**Shareholders**") and potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 (the "**First Half of 2026**") and information currently available to the Company, the Group is expected to record (i) a revenue in the range of approximately USD102.5 million to approximately USD106.5 million for the First Half of 2026, representing an increase of approximately 272.7% to 287.3% compared to the revenue of USD27.5 million for the six months ended June 30, 2025; (ii) a net profit in the range of approximately USD33.5 million to approximately USD39.5 million for the First Half of 2026, as compared to the net loss of USD19.2 million for the six months ended June 30, 2025; and (iii) an adjusted non-IFRS net profit in the range of approximately USD45.5 million to approximately USD51.5 million for the First Half of 2026, as compared to the adjusted non-IFRS net loss of USD15.4 million for the six months ended June 30, 2025.

The adjusted non-IFRS net profit/loss is defined as profit/loss for the period adjusted by adding back (i) loss or gain from changes in fair value of financial liabilities at fair value through profit or loss, (ii) share-based compensation expenses and (iii) listing expenses.

The Board believes that the increase in revenue, net profit and adjusted non-IFRS net profit of the Group for the First Half of 2026 is mainly due to the Group's continuous efforts in driving revenue growth, including the significant increase in the Group's revenue from out-licensing, co-development, and research collaboration agreements for the First Half of 2026, as compared to the revenue for the six months ended June 30, 2025, together with the systematic improvement of operating efficiency.

The Company is still in the process of finalizing its interim results of the Group for the First Half of 2026. The information contained in this announcement is solely based on a preliminary assessment by the Board with reference to the unaudited consolidated management accounts and information currently available, which have not been audited or reviewed by the auditor or the audit committee of the Company, and are subject to adjustments where necessary. Shareholders and potential investors of the Company should refer to and carefully read the interim results announcement of the Company for the First Half of 2026, which is expected to be published in August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, July 9, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.